Work

THU0198 Immunogenicity associated with a transition from adalimumab reference product to abp 501 in patients with rheumatoid arthritis

Year: 2018

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2018-eular.7225

Authors: E. Krishnan, D. Mytych, N. Zhang, H. Wang, A. Kaliyaperumal

Institution: Amgen (United States)

Language: English

Topic: Biosimilars and Bioanalytical Methods

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Pfizer, Karolinska Institutet, Samsung

OpenAlex ID: W2908797017

Cites:

Cited by: 3

Related to: 10